
TRAX Stock Forecast & Price Target
TRAX Analyst Ratings
Bulls say
First Tracks is in a strong financial position, with sufficient funding to support its pipeline development and continued research efforts. The company's focus on delivering immunology therapeutics for multiple autoimmune and inflammatory diseases positions it well for long-term success in the biotech market. Its strategic partnerships with pharmaceutical companies also provide opportunities for future growth and advancements in therapeutic development.
Bears say
First Tracks is at a high risk of not being able to bring its immunology therapeutics to market due to its reliance on external contractors for manufacturing, as any delay in their activity could significantly delay development timelines. Additionally, while their lead asset ANB033 has shown potential in its Phase 1a trial, the lack of ongoing trials in EoE for therapies with similar mechanisms of action raises concerns about the market opportunity and potential competition in this indication. Further validation of ANB033's mechanism of action through competitor readouts may be a key stock-moving event, but overall the company's early stage of development and lack of data in key indications increase the financial risks associated with investing in this stock.
This aggregate rating is based on analysts' research of First Tracks Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TRAX Analyst Forecast & Price Prediction
Start investing in TRAX
Order type
Buy in
Order amount
Est. shares
0 shares